Therapeutic effect of Peg-IFN therapy combined with RBV and telaprevir(TVR) on patients with chronic hepatitis C

Therapeutic effect of Peg-IFN therapy combined with RBV and telaprevir(TVR) on patients with chronic hepatitis C - Therapeutic effect of telaprevir(TVR) on patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013743

Enrollment

300

Registered

2014-04-18

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Peg-IFN-alpha2b/RBV/telaprevir 12 weeks plus Peg-IFN-alpha2b/RBV 12 weeks: a total of 24 weeks treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C patients with HCV serotype 1 laboratory data before study treatment neutrophil count over 1,500/mm3 platelet count over 100,000/mm3 hemoglobin over 12g/dl

Exclusion criteria

Exclusion criteria: Patients who did not fulfill the criteria to receive the approved Peg-IFN-alpha2b/RBV/telaprevir treatment

Design outcomes

Primary

Measure	Time frame
sustained virologic response rate	—

Countries

Japan

Contacts

Public ContactAkihiro Moriuchi

Kagoshima university Division of digestive and lifestyle disease

akimori@m2.kufm.kagoshima-u.ac.jp099-275-5326

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026